Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
Parkinsonism Relat Disord
; 20(4): 452-5, 2014 Apr.
Article
em En
| MEDLINE
| ID: mdl-24521874
ABSTRACT
BACKGROUND:
The antiepileptic drug topiramate reduces levodopa-induced dyskinesia without exacerbating parkinsonism in animal models. We report a randomized, double-blind, placebo-controlled crossover trial in patients with Parkinson's disease and levodopa-induced dyskinesia.METHODS:
Fifteen patients with Parkinson's disease and stable levodopa-induced dyskinesia were enrolled into the study, of whom 13 were randomized to topiramate or placebo. The study medication was titrated to 100 mg/day over four weeks, and assessments were carried out after a further two weeks. Dyskinesia severity assessed by a blinded rater from video recordings was the primary outcome measure.RESULTS:
Seven patients (mean age 58.9 ± 12.8 years) completed the study. Patients taking topiramate vs. placebo showed a significant increase in dyskinesia severity compared to baseline (Wilcoxon signed rank test, P = 0.043). Five patients withdrew from the study whilst taking topiramate due to adverse effects.CONCLUSIONS:
Topiramate tended to worsen dyskinesia in patients with Parkinson's disease, and was poorly tolerated.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doença de Parkinson
/
Discinesia Induzida por Medicamentos
/
Frutose
/
Anticonvulsivantes
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article